Comparative Pharmacology
Head-to-head clinical analysis: BRONKAID MIST versus BROVANA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRONKAID MIST versus BROVANA.
BRONKAID MIST vs BROVANA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Epinephrine, the active ingredient, is a direct-acting sympathomimetic amine that stimulates alpha- and beta-adrenergic receptors. Beta-2 receptor activation in bronchial smooth muscle causes bronchodilation. Alpha receptor activation causes vasoconstriction, reducing mucosal edema.
BROVANA (arformoterol tartrate) is a long-acting beta2-adrenergic agonist (LABA). It stimulates intracellular adenyl cyclase, increasing cyclic AMP levels, leading to relaxation of bronchial smooth muscle and inhibition of mast cell mediator release.
2 inhalations (200 mcg per inhalation) every 4 hours as needed for bronchospasm. Maximum 12 inhalations in 24 hours.
15 mcg (2 mL) by nebulization twice daily, not to exceed 30 mcg/day.
None Documented
None Documented
Terminal elimination half-life: 3-6 hours; clinical context: shorter half-life in children, prolonged in hepatic impairment; requires frequent dosing
Terminal elimination half-life: approximately 26 hours (range 22–30 hours) in healthy adults; prolonged in hepatic impairment (up to 50% increase).
Renal: 40-70% unchanged; fecal: minor (biliary) <5%
Primarily renal (60% unchanged drug); remainder via biliary/fecal (approximately 20%) and metabolic transformation.
Category C
Category C
Bronchodilator
Bronchodilator